Journal of Immunological Techniques & Infectious Diseases .ISSN: 2329-9541

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Market Analysis, J Immunol Tech Infect Dis Vol: 8 Issue: 2

Market Analysis of Orphan Drugs 2020

Ahmed Hegazi

Emeritus Professor,Department of Immunology, National Research Center, Egypt, E-mail: [email protected]

Keywords: Drugs, Orphan

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.

Why to organize this conference?

1. To share learning and best follow from thought leaders and specialists in the field of Orphan Drugs.

2. To engage with compatible individuals with shared interests.

3. To inspire and generate awareness to rare diseases.

4. To make a discussion about the diseases and betterment of its treatment.

5. To form new partnerships all over the world.

6. To get results and diffuse messages face to face in an exceedingly value effective manner.

7. To provoke action and collectively bring the evolution in the field of Rare Diseases and its treatment.

8. To network and meet new people and organisations who are professional in the field of Orphan Drugs.

9. To encourage PR and media coverage.

Importance & Scope

There are greater than 6000 Rare Diseases. Many rare diseases are identified at the age of childhood, making diagnostic awareness and understanding on treatment and care specifically necessary for paediatricians. The Rare Diseases are so rare that rarity can lead to various troubles including: difficulties in obtaining timely, correct diagnoses; lack of experienced healthcare supervisors; useful, dependable and well timed statistics may additionally be challenging to retrieve; lookup things to do are very less; growing new prescribed drugs can also not be economically feasible; treatments are on occasion very expensive; and indeveloping countries, the issues are compounded via different resource limitations.

Orphan Drug 2020 is emerging up with an exciting and excessive knowledge gaining convention application this yr also which includes plenary lectures, symposia, workshops on a range of topics, poster shows and a number packages for contributors from at some stage in the world. We welcome you to join us at the International Conference on Orphan Drugs and Rare Diseases in

Berlin the place you will be sure to have a significant ride with scholars from around the world. The Rare Diseases Conference aims to extend the reach, impact and trade of scholarly thoughts via revolutionary technology, determined commitment and awesome service. It objectives to provide international collaboration and trade of complete and ultra-modern data on basic, translational, and utilized medical research on Rare iseases and Orphan Drugs. The field of rare disease products is continuously growing, expecting to reach $180 billion by 2020, with a CGR of 10.5% just for orphan drugs – this is twice the growth rate of the overall prescription drug market.

Every year, lives are lost because of the spread of infections in hospitals. Health care workers can take steps to prevent the spread of infectious diseases. These steps are part of infection control. Infection prevention and control measures aim to ensure the protection of those who might be vulnerable to acquiring an infection both in the general community and while receiving care due to health problems, in a range of settings. The basic principle of infection prevention and control is hygiene. Healthcare personnel might need to take additional infection control steps if a PUI or patient with confirmed EVD has other conditions or illnesses caused by specific infectious diseases, such as tuberculosis. Healthcare personnel can be exposed to Ebola virus by touching a patient’s body fluids, contaminated medical supplies and equipment, or contaminated environmental surfaces. Splashes to unprotected mucous membranes (for example, the eyes, nose, or mouth) are particularly hazardous. Procedures that can increase environmental contamination with infectious material or create aerosols should be minimized. healthcare personnel (HCP) refers all people, paid and unpaid, working in healthcare settings who have the potential for exposure to patients and/or to infectious materials, including body substances, contaminated medical supplies and equipment, contaminated environmental surfaces, or aerosols generated during certain medical procedures. HCP include, but are not limited to, physicians, nurses, nursing assistants, therapists, technicians, emergency medical service personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual personnel, home healthcare personnel, and people not directly involved in patient care (clerical, dietary, housekeeping, laundry, security, maintenance, billing, chaplains, and volunteers) but potentially exposed to infectious agents that can be transmitted to and from HCP and patients.

Rare Diseases are that affects a small percentage of the population all over the world. An Orphan Disease is Rare Diseases with a lack of a market large enough to gain support and sources for discovering treatments for it, with advances to research in orphan diseases advantageous conditions to creating and selling such treatments. Rare diseases are genetic and are present throughout the entire life of individual suffering, even if symptoms do not immediately appear.

Many Rare Diseases seems to appear early in life, and about 30% of children affecting with rare paediatric diseases will die before getting 5 year old. Rare Diseases are generally genetic and so they chronic. It is estimates that at least 80% of them have identified genetic origins. Other Rare Diseases are the result of infections and allergies or it may be due to degenerative and proliferative causes and discovering the well-advanced treatments in Rare Diseases and Orphan Drugs.

The urbanization of the human people is on the peril of transmission of numerous irresistible advertisers. Right now, >80% of individuals live in developing nations, rising event of irresistible infirmities, developing use to upgrade the entrance cost of cures of these ailments, developing undertakings and making awareness around medicines and finding of those circumstances, and developing logical preliminary research for development of late pills are no doubt to be the components chargeable for blast of this commercial center. Nonetheless, absence of learning and medications for these disarranges and low appropriation of cures is elements to restriction the development in the coming years.

Track Your Manuscript

Recommended Conferences

Share This Page

Media Partners